Navigation Links
Key to 'curing' obesity may lie in worms that destroy their own fat: McGill researchers
Date:12/8/2008

This release is available in French.

A previously unknown mutation discovered in a common roundworm holds the promise of new treatments for obesity in humans, McGill University researchers say. Their study was published Dec. 3 in the journal Nature, and was funded by the Canadian Cancer Society and the Canadian Institutes of Health Research.

In lean times, a normal Caenorhabditis elegans worm goes into a form of suspended animation called "dauer" that slows its metabolism and allows it to survive for extended periods without food.

"When they go into dauer, these worms radically alter their metabolism," said Dr. Richard Roy, a cancer researcher at McGill's Department of Biology specializing in the control of cell division. "They shut down everything energy-consuming, which includes foraging, cell division and reproduction."

Unlike other "hibernating" organisms, C. elegans maintains a degree of mobility during dauer by stocking up on energy in the form of fats or lipids which they store in special cells or reserves.

"This allows them to live up to six months without eating, instead of the two weeks they would otherwise have," Roy explained. A worm with the newly discovered mutation, however, will usually die within a week of going into dauer

"These mutants somehow cannot shut down the process of cell division, which is why we noticed them in the first place," Roy said. "However, that's not what kills them. They cannot adjust their metabolism correctly. They store up their six-month lipid reserves, but as soon as they shift into dauer they use them up within a few days. This is because they lack an enzyme that blocks the activity of a very important triglyceride lipase. Without this regulation the lipase burns up all the fat it encounters and destroys the worm's energy reserves."

This discovery was a near-accidental by-product of Roy's regular line of research, searching for cells that abnormally disobey cellular signals in a cancer context, and he gives graduate student and study first author Patrick Narbonne much of the credit.

"Patrick was absolutely brilliant. He was so observant that he noticed these animals were dying way too early, and he also realized that they were not dying because of the cell-division issue."

Roy and Narbonne believe this discovery, which will require considerable additional research, may have significant long-term implications for human health.

"I think we should start looking at the enzymes involved in this cascade, particularly in obese individuals. They are likewise accumulating lipids, but in a reverse situation to C. elegans, this enzyme isn't recognizing it, or something is blocking its function. We're making the case that we can uncouple this enzyme from its normal regulation. If we could develop drugs to do that selectively in fatty tissue, we'd be able to chew up all the fat."

"This study fascinates me," said Dr. Robert Sladek, one of Canada's most prominent diabetes researchers, affiliated to the McGill Department of Human Genetics and the McGill and Genome Quebec Innovation Centre. "It will be exciting to see whether this pathway that controls energy storage and lifespan in worms plays a similar role in humans. The implications for patients with obesity and diabetes might be quite far-reaching."


'/>"/>

Contact: Mark Shainblum
mark.shainblum@mcgill.ca
514-398-2189
McGill University
Source:Eurekalert

Related biology news :

1. Securing the future of Europes biological data resources
2. Childrens National convenes first childhood obesity symposium
3. Persistent pollutant may promote obesity
4. Adiponectin is a metabolic link between obesity and bone mineral density
5. UNC study: Text messaging may help children fight off obesity
6. 15-state Southern obesity summit to focus on deadly epidemic
7. A new weapon in the fight against obesity and diabetes
8. Scientists from Granada find a potential treatment to prevent diabetes and obesity
9. Color My Pyramid nutrition education program battles obesity in DC schools
10. Making metabolism more inefficient can reduce obesity
11. Scientists discover why a mothers high-fat diet contributes to obesity in her children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... , November 29, 2016 Nearly one billion matches ... Reading ... DERMALOG ... of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's ...
(Date:11/22/2016)... According to the new market research report "Biometric System Market ... Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, and Region ... to grow from USD 10.74 Billion in 2015 to reach USD 32.73 ... Continue Reading ... ...
(Date:11/19/2016)... -- Securus Technologies, a leading provider of civil and ... and monitoring, announced today that it has offered a ... independent technology judge determine who has the largest and ... calling platform, and the best customer service. ... what we do – which clearly is not the ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... ... December 08, 2016 , ... Microbial genomics ... Awards. uBiome is one of just six company finalists in the Health & ... to uBiome, companies nominated as finalists in this year’s awards include Google, SpaceX, ...
(Date:12/8/2016)... -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), ... products to treat rare diseases where there is an ... hosting an Investor Webcast Event Friday, December 16, 2016, ... defense regulators (IDRs) as a new drug class, as ... recently announced and published Phase 2 clinical data for ...
(Date:12/8/2016)... Eutilex Co. Ltd. today announced that it ... A financing. This financing round included participation from DS ... Bio Angel. This new funding brings the total capital ... since its founding in 2015. The ... commercialization of its immuno-oncology programs, expand its R&D capabilities ...
(Date:12/7/2016)... ... 07, 2016 , ... ACEA Biosciences, Inc. presented today updated ... trial for its lead drug candidate, AC0010, at the World Conference on Lung ... determine the safety, antitumor activity, and recommended phase II dosage of AC0010 in ...
Breaking Biology Technology: